Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274688 | 1.00 | PTPN11 (0.37) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| SCHEMBL29352364 | 1.00 | PTPN11 (0.37) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| SCHEMBL21383761 | 1.00 | PTPN11 (0.37) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| SCHEMBL22493782 | 1.00 | PTPN11 (0.37) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL31033471 | 0.98 | PTPN11 (0.36) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL21383746 | 0.98 | PTPN11 (0.36) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL28960494 | 0.98 | PTPN11 (0.36) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL21383835 | 0.98 | PTPN11 (0.36) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL21384023 | 0.98 | PTPN11 (0.36) | PTPN11HTR2AKCNH2DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL30529389 | 0.98 | PTPN11 (0.36) | PTPN11HTR2AKCNH2DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | claimed |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12233062-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240285617-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240245681-A1 | HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBO PHARMACEUTICATS CO LTD (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-117263942-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2021148010-A1 | PYRAZOLO HETEROARYL RING COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-07-29 | — | — | WO | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3768668-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112166110-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2021-01-01 | — | — | CN | disclosed |
| WO-2020210384-A1 | PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-10-15 | — | — | WO | disclosed |
| CN-111295374-A | Aza-containing aromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2019183367-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183367-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | PTPN11 13/4885HTR2A 3938/4885KCNH2 4068/4885 |
| US-20240245681-A1 | HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN2 | PTPN11 11/4885HTR2A 4235/4885KCNH2 4262/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | PTPN11 14/4885HTR2A 4480/4885KCNH2 4635/4885 |
| US-20240285617-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN2 | PTPN11 9/4885HTR2A 4302/4885KCNH2 4301/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | PTPN11 20/4885HTR2A 4287/4885KCNH2 4731/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | PTPN11 14/4885HTR2A 4480/4885KCNH2 4635/4885 |
| US-12233062-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPN1, PTPN5, PTPN2 | PTPN11 11/4885HTR2A 4235/4885KCNH2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.